Purple Tephrosia (Tephrosia purpurea (L.) Pers.): A Comprehensive Reference
1. Identity: Botanical Name, Natural Source, and Common Forms
1.1 Nomenclature and Taxonomy
Tephrosia purpurea is a plant belonging to the Fabaceae (pea) family and is a well-known Ayurvedic herb, commonly known as Sarapunkha (also spelled Sharapunkha, Sharpunkha, or Sarpunkha) in the traditional Indian medicinal system.
The accepted full binomial with authority is Tephrosia purpurea (L.) Pers., indicating that the species was first described by Linnaeus and later placed in the genus Tephrosia by Christiaan Hendrik Persoon. A former synonym is Cracca purpurea L. The genus name Tephrosia derives from the Greek tephros, meaning ash-coloured, a reference to the hoary or grey appearance of many species in the genus.
Tephrosia purpurea has two recognized subspecies: leptostachya (DC.) Brummitt and apollinea (Delile) Hosni and El-Karemy, both of which grow in Egypt.
The subspecies apollinea was initially named Galega apollinea by Alire Raffeneau Delile in 1813, and moved to the genus Tephrosia by Johann Heinrich Friedrich Link in 1822. Its current treatment as a subspecies of Tephrosia purpurea was proposed by Hasnaa A. Hosni and Zeinab A. R. El-Karemy in 1993, after finding that their previous descriptions "agree in most of their characters."
The plant is also referred to by synonyms including Cracca purpurea and the common names Sharpunkha and Meghapatti.
In parts of southern Arabia, the species carries the vernacular name of hailara, and is also known as dhafra, dhawasi, omayye, or nafal to Arabs. In the Sinai area of Egypt, it is referred to by the Bedouin as sanna or senna. It is also known as amioka in parts of Sudan. Due to its traditional use in making indigo dyes, Tephrosia purpurea has also been referred to as "Egyptian indigo."
1.2 Botanical Description and Natural Habitat
Purple Tephrosia is an erect or spreading annual or short-lived perennial herb, sometimes bushy, usually growing from 40–80 cm tall, rarely up to 1.5 metres.
Leaves are pinnate with 7–13 leaflets, each 2–4 cm long, deep green above and paler beneath. Its signature purple pea-flowers appear in clusters, later forming elongated pods about 5–7 cm long.
Pods are 2.5–4 × 0.3–0.4 cm, linear-oblong, and 5–7-seeded. Seeds are ellipsoid and dark brown.
Geographically, T. purpurea is found at an altitude between 400 m to 1300 m in countries including India, Sri Lanka, China, and Australia. Its natural habitat is in dry, sandy, or rocky soil, and it is often seen growing along the roadside and in places where waste is dumped.
The genus Tephrosia belongs to the family Fabaceae and is widespread in tropical and subtropical regions of the world.
The subspecies apollinea is specifically distributed in the Nile Delta, Nile banks, and desert wadis, especially Wadi Allaqi (Nubia), Gebel Elba (southern Egypt), and Sudan.
1.3 Plant Parts Used and Common Preparations
Useful parts of the plant include the root, leaves, seeds, and bark.
The most common and versatile form of the herb is its powder (churna), made by drying and grinding the plant's roots, leaves, or seeds.
A decoction (known as kwath in Ayurveda) is a more concentrated form, prepared by boiling the plant parts in water. This decoction can be consumed in doses of 10–20 ml and is used for treating liver conditions and improving digestive function.
The general method of preparation of decoction (kashaya) involves adding one tablespoon of powder to 2 cups of water, boiling and reducing to 1 cup, then filtering.
The plant is also incorporated into standardized multi-herb Ayurvedic formulations. It is widely used in formulations like Tephroli and Yakrifit for liver disorders, respiratory ailments, dermatological conditions, and metabolic dysfunctions. Modern commercial preparations include capsules, tablets, standardized extracts, topical ointments, and liquid syrups.
2. Traditional and Historical Use
2.1 Ayurvedic Tradition (India)
Tephrosia purpurea is popularly known as 'Sarapunkha' in classical Ayurvedic texts. It is a perennial plant belonging to the family Fabaceae, and occurs throughout the Indian subcontinent. It is traditionally used to treat splenomegaly, cirrhosis, cough and cold, abdominal swelling, and as an antidote in the Ayurvedic system of medicine.
Described in classical texts as "Sarwa wranvishapaka," meaning having the capability to heal all types of wounds, it is particularly recognized for its usage in splenomegaly.
In Ayurveda, this plant is used as a remedy for impotency, asthma, diarrhea, gonorrhea, rheumatism, ulcer, and ailments of the kidney, liver, spleen, heart, and blood. The dried herb is considered tonic and has healing activity for leprous wounds.
The leaves are characterized in classical Ayurveda as laxative, cholagogue (Pitta saraka), diuretic, blood purifier, wormicidal, and antipyretic in nature. The drug is thus used in hemorrhoids, obstructive and infective liver disorders, splenomegaly, and anemia.
Fresh juice of the leaves, administered along with honey, is used in all age groups, preferably in children, to pacify dry cough, cold, and rhinitis.
Root decoction made from 3–5 grams of the root, administered along with half a teaspoon of jaggery or palm jaggery, is used for indigestion, flatulence, and loss of taste or hunger, as it is said to improve digestion and relieve gas.
Tephrosia purpurea (Linn.) Pers., a popular Indian medicinal plant, has long been used commonly in the Ayurvedic and Unani systems of medicine.
It is an important component of herbal preparations like Tephroli and Yakrifti, used to cure liver disorders.
In clinical records, the Tefroli tablet formulation was reported to be well tolerated, with no side effects noticed in any of 32 cases during the treatment of viral hepatitis. Yakrifit, a liver tonic of T. purpurea, was found clinically effective for veterinary uses.
2.2 Traditional Use in Arabia, North Africa, and Sudan
The leaves and root have been used in traditional medicine for bronchitis, cough, earache, wounds, and bone fractures by herbalists in countries such as Oman and the United Arab Emirates. The ground leaves of Tephrosia purpurea are also insufflated in cases of nasal congestion, or boiled with water to make eardrops.
Powdered bark can be mixed with water and poured into the ears of camels with ticks, and powdered leaves have been made into a paste to be smeared on wounds.
It is used in the treatment of leprosy, ulcers, asthma, and tumors, as well as diseases of the liver, spleen, heart, and blood. A decoction of the roots is given in dyspepsia and diarrhea.
2.3 Traditional Use as a Fish Poison and Insecticide
The plant contains rotenoids and has been used traditionally as a fish poison — rotenoids kill or stun fish, making them easy to catch, while the fish remain perfectly edible for mammals.
In Africa and South America, Tephrosia spp. are used for fishing poisons by peasant and original populations.
3. Key Constituents and Active Compounds
3.1 Overview of Phytochemical Classes
Phytochemical investigations on Tephrosia purpurea reveal the presence of constituents such as carbohydrates, protein, amino acids, tannins, saponins, terpenes, flavanones, rotenoids, chalcones, isoflavones, glycosides, alkaloids, flavanols, and sterols.
The broad spectrum of biological effects of the plant is primarily attributed to its rich phytochemical composition, including flavonoids, phenolics, rotenoids, alkaloids, and glycosides, which are thought to act synergistically to modulate multiple biochemical pathways.
3.2 Rotenoids
Modern research has identified key bioactive constituents including flavonoids (quercetin, rutin), rotenoids (tephrosin, deguelin), and terpenoids (lupeol, β-sitosterol) that underlie its pharmacological properties.
The leaves are rich in tephrosin, deguelin, isotephrosin, rotenone, and osyritin.
Rotenoids are a class of isoflavonoid-related compounds characterized by their inhibition of mitochondrial Complex I (NADH-ubiquinone reductase), which underlies both their insecticidal potency and certain anticancer mechanisms studied preclinically.
3.3 Flavonoids, Isoflavones, and Chalcones
Phytochemical investigations indicate the presence of semiglabrin, pongamole, lanceolatins A and B, rutin, lupeol, and β-sitosterol. Flavonoids including (+)-tephrorin A and B, (+)-tephrosone, an isoflavone 7,4′-dihydroxy-3′,5′-dimethoxyisoflavone, and a chalcone (+)-tephropurpurin were isolated from the whole plant.
A new naturally occurring flavonol diglycoside, tamarixetin 3-O-β-glucopyranoside-7-O-α-rhamnopyranoside, was isolated along with two known flavonol diglycosides from the aerial parts of Tephrosia purpurea (L.) Pers. (Fabaceae).
Chemical investigations of aerial parts of Tephrosia purpurea have yielded the rare prenylated flavonoids tephropurpulin A (1) and isoglabratephrin (2), in addition to a previously identified flavonoid, glabratephrin (3).
Quantitative HPLC profiling of T. purpurea subsp. apollinea identified quercetin (6.76 mg/100 g dry weight) and rutin (0.76 mg/100 g dry weight) as the main flavonoids, and also the flavonol kaempferol (2.29 mg/100 g dry weight) and the flavanone naringenin (0.12 mg/100 g dry weight), as well as hesperetin (0.06 mg/100 g dry weight).
The identified phenolic acids included gallic acid (1.24 mg/100 g dry weight) and ferulic acid (0.14 mg/100 g dry weight). Chlorogenic acid (8.10 mg/100 g dry weight), pyrocatechol (0.36 mg/100 g dry weight), and coumaric acid (0.15 mg/100 g dry weight) were also identified.
3.4 Terpenoids, Sterols, and Other Compounds
Various phytocompounds including pongamol, purpurin, purpurenone, tephrosin, bulnesol, tephrostachin, and β-sitosterol have been reported from the plant.
GC-HRMS analysis confirmed the presence of 2-methoxy-4-vinylphenol, sucrose, n-hexadecanoic acid, 9,12-octadecadienoic acid, and oleic acid. Based on ICP-OES analysis, essential metal ions including calcium, magnesium, iron, cobalt, copper, zinc, and selenium were also detected.
A naturally occurring novel compound, benzofuran, was isolated from T. purpurea and confirmed to have suppressive activity toward H1 histamine receptor gene expression.
4. Established Mechanisms of Action
4.1 Anti-inflammatory Mechanisms
Among the known active compounds of T. purpurea, quercetin, rutin, β-sitosterol, and lupeol are mainly responsible for its anti-inflammatory and anti-cancer properties.
These compounds are known to inhibit pro-inflammatory mediators, with quercetin and rutin documented to modulate arachidonic acid metabolic pathways, NF-κB signaling, and pro-inflammatory cytokine expression in in-vitro and animal models.
4.2 Hepatoprotective Mechanisms
The ethyl acetate fraction of ethanolic extract of T. purpurea was investigated for hepatoprotective activity against carbon tetrachloride-induced hepatocellular injury. In these investigations, the extracts significantly reduced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin, and also reduced necrosis and inflammation compared with the toxic group.
Higher lipid peroxidation (LPO) and lower glutathione levels were also reversed. These activities were attributed to the presence of polyphenolic compounds and flavonoids in the extracts.
The plant exhibits notable hepatoprotective effects by modulating oxidative stress and liver enzymes.
4.3 Antidiabetic Mechanisms
The plant shows antidiabetic potential through AMPK (AMP-activated protein kinase) activation.
In streptozotocin-induced diabetic rats, hyperglycemia was associated with altered hexokinase and glucose-6-phosphatase activities, elevated lipid peroxidation, and disturbed antioxidant status. Oral administration of ethanolic seed extract at a dose of 300 mg/kg body weight showed significant antihyperglycemic and antilipidperoxidative effects and increased the activities of enzymatic antioxidants and levels of non-enzymatic antioxidants. The antihyperglycemic effect was comparable to that of the reference drug glibenclamide.
4.4 Anticancer Mechanisms
Tephrosin acts through multiple pathways: inhibiting NF-κB signaling, autophagy, and inducing apoptosis, inhibiting kinases, reducing growth factor phosphorylation, and blocking pathways like PI3K/Akt.
In HepG2 hepatocellular carcinoma cells, leaf and root extracts inhibited cell growth at an IC50 of 102.33 ± 10.26 µg/mL and 276.67 ± 20.43 µg/mL respectively at 24 hours. These extracts induced cell shrinkage, DNA condensation and fragmentation, mitochondrial membrane depolarization, and upregulated caspase-3 expression, indicating that T. purpurea extracts induce apoptosis in HepG2 cells.
4.5 Acetylcholinesterase Inhibition
Acetylcholinesterase inhibitory action has been reported from this plant, which aids its utilization for the development of drugs for Alzheimer's and dementia neurological disorders.
The compound tephrostachin is specifically responsible for antiplasmodial activity, while tephrosin, pongaglabol, and semiglabrin exert antiulcer activity.
5. Scientific Evidence by Area of Use
5.1 Hepatoprotective (Liver-Protective) Activity
Evidence level: Preclinical (animal and in vitro) only; very limited formal human clinical data.
Commercially, T. purpurea is a critical component in hepatoprotective formulations (e.g., Tefroliv Forte, GD-Liv Syrup) for treating hepatitis, cirrhosis, and drug-induced liver damage.
Multiple animal models have been used to study the hepatoprotective effects. The ethyl acetate fraction of ethanolic extract was investigated against CCl4-induced hepatocellular injury. The extracts significantly reduced serum ALT, AST, alkaline phosphatase, total bilirubin, and also reduced necrosis and inflammation, with these activities attributed to the presence of polyphenolic compounds and flavonoids.
In one clinically relevant report, Tefroli tablet (containing T. purpurea) was described as well tolerated, with no side effects noticed in any of 32 cases during treatment of viral hepatitis.
This is a very small case series rather than a controlled clinical trial, and the evidence for liver-protective effects in humans remains limited and not formally validated by randomized controlled trials.
5.2 Antidiabetic Activity
Evidence level: Preclinical (animal models) only; no adequate human clinical trials identified.
A study in Springer's Indian Journal of Clinical Biochemistry evaluated the antihyperglycemic and antilipidperoxidative effects of ethanolic seed extract of T. purpurea (TpEt) in streptozotocin-induced diabetic rats. Oral administration of TpEt at a dose of 300 mg/kg body weight showed significant antihyperglycemic and antilipidperoxidative effects and increased the activities of enzymatic antioxidants and non-enzymatic antioxidants. The antihyperglycemic effect was comparable to that of the reference drug glibenclamide.
The aqueous extract of the whole plant also exhibited notable antidiabetic activity (68.45 ± 4.23%) in in vitro assay conditions.
These findings are preliminary and restricted to animal and in vitro models. No robust human clinical trials have been published.
5.3 Anti-inflammatory Activity
Evidence level: Preclinical (animal and in vitro); no controlled human clinical trials identified.
Pharmacological activities of different parts of the plant reported include anti-inflammatory, antiulcer, antimicrobial, antioxidant, antiallergic, antidiabetic, hepatoprotective, antitumor, and insect repellent activity.
The aqueous extract of the whole plant showed anti-inflammatory properties with a binding constant value of 5.23 ± 0.04 × 10−5 µM−1.
Anti-inflammatory studies have primarily used animal models (e.g., rat paw edema), with results attributed to the plant's rotenoid and flavonoid content. No human trials have been conducted on anti-inflammatory endpoints.
5.4 Wound Healing
Evidence level: Preclinical (animal models); no controlled human clinical trials identified.
A study published in the Journal of Ethnopharmacology (PubMed PMID: 16806763) investigated the wound healing potential of ethanolic extract of Tephrosia purpurea aerial parts in the form of a simple ointment using three types of wound models in rats: incision wound, excision wound, and dead space wound. The results were comparable to the standard drug Fluticasone propionate ointment, in terms of wound contraction, tensile strength, histopathological, and biochemical parameters such as hydroxyproline content and protein level. Histopathological study showed significant (P < 0.05) increase in fibroblast cells, collagen fibres, and blood vessels formation.
A further study evaluated wound healing effects of the ethyl acetate fraction of T. purpurea (TPF-A) in dead-space and burn wound models in rodents. An ointment (5% w/w) of TPF-A, along with isolates pongamol and luteolin, was applied topically twice a day, and effects were compared with Povidone Iodine ointment with respect to protein, collagen content, enzymatic assay, and histopathological findings.
These findings are consistent with, but limited to, animal models.
5.5 Anticancer and Antitumor Activity
Evidence level: In vitro (cell lines) and limited animal models only; no human clinical trials identified.
Several studies have revealed that the flavonoids and phenolic components of the genus Tephrosia have potent pharmacological effects, including anticancer properties, especially against the human breast cancer cell line MCF-7.
A study (PMC5407109) investigated the anti-cancer potential of T. purpurea on hepatocellular carcinoma (HCC), as this aspect was poorly understood. Leaf and root extracts were obtained with methanol using soxhlet apparatus. Cytotoxicity in HepG2 cells was evaluated using MTT assay, and mode of cell death was examined by AOEB, Hoechst, and JC1 staining. Leaf and root extracts inhibited HepG2 cell growth at the IC50 of 102.33 ± 10.26 µg/mL and 276.67 ± 20.43 µg/mL respectively at 24 hours. These extracts induced cell shrinkage, DNA condensation and fragmentation, mitochondrial membrane depolarization, and upregulated caspase-3 expression, indicating induction of apoptosis.
However, the plant extract had no adverse effects on normal cells (WI38) at an IC50 of 242.9 ± 1.8 µg/mL, indicating some degree of selectivity.
All anticancer evidence remains in vitro and/or animal-model based; no human clinical trials exist.
5.6 Antimicrobial Activity
Evidence level: In vitro only; no clinical trials identified.
The ethanolic extracts of Tephrosia purpurea have been reported to possess potential antibacterial activity, and flavonoids were found to have antimicrobial activity.
The aqueous extract of the whole plant showed antimicrobial activity with MIC (minimum inhibitory concentration) values of 23–52 mg/ml in in vitro studies.
These findings are limited to laboratory conditions and do not constitute clinical evidence of efficacy in treating human infections.
5.7 Antiplasmodial (Antimalarial) Activity
Evidence level: In vitro and animal models only.
The stem extract of Tephrosia purpurea showed antiplasmodial activity against the D6 (chloroquine-sensitive) and W2 (chloroquine-resistant) strains of Plasmodium falciparum.
Various extracts and isolates of T. purpurea have shown a wide range of biological activities including antiplasmodial activity, and were also shown to be applicable to treat Helicobacter pylori infection.
No human clinical trials for malaria have been conducted.
5.8 Antioxidant Activity
Evidence level: In vitro studies; no clinical trials identified.
The aqueous extract of T. purpurea (whole plant) exhibited antioxidant potential greater than 65% in in vitro studies.
The total phenolic content of aerial parts of T. purpurea subsp. apollinea was 39.12 mg GAE/g dry weight, and total flavonoids amounted to 17.83 mg CE/g dry weight.
These values reflect the significant polyphenol load of the plant, which underlies its free-radical scavenging capability measured in vitro.
5.9 Cardioprotective Activity
Evidence level: Animal models only.
Tephrosia purpurea is used as a treatment for the heart in Ayurveda traditional medicine in India. Treatment of diabetic rats with aqueous extract (300 and 500 mg/kg orally) decreased cardiac left ventricular hypertrophy (LVH) at both doses, and reduced LDH and CK at the dose of 500 mg/kg. The extract improved cardiac histopathological changes, heart rate, and ±dp/dt in the diabetic group by reversing fiber disarray and degeneration, and attenuated vacuole formation in the cardiac tissue of STZ-induced diabetic rats.
Preclinical studies further demonstrate its potential in cardiovascular protection, cataract prevention, and lipid regulation.
These findings are from animal models only.
5.10 Neuroprotective and Neurological Activity
Evidence level: In vitro and animal models only.
Acetylcholinesterase inhibitory action has been reported from this plant, which aids its potential utilization in the development of drugs for Alzheimer's and dementia neurological disorders.
Neuroprotective and anti-obesity activities are attributed to anti-inflammatory and apoptotic mechanisms.
No human clinical trials have been conducted in the neurological domain.
5.11 Antifertility and Antispermatogenic Activity
Evidence level: Animal models only; this activity represents a potential safety signal, not a therapeutic use.
Histopathological observations of the testis after Tephrosia purpurea treatment showed degenerated germinal epithelium of seminiferous tubules and reduced number of sperms in a dose-dependent manner.
Treatment at 50 mg/kg showed a few lesions affecting the tubules, while rats treated with 100 and 200 mg/kg/body weight/day affected almost all tubules; however, spermatogenesis recovered to near-normal levels in recovery-group rats.
This animal study data indicates a possible reversible antispermatogenic effect at higher doses, which warrants caution.
6. Body Systems and Health Areas of Association
Based on the compiled traditional use and preclinical scientific evidence, Tephrosia purpurea is associated with the following body systems:
- Hepatobiliary system: Traditionally used to treat splenomegaly, cirrhosis, cough and cold, abdominal swelling, and as an antidote in Ayurvedic medicine. Most extensively studied preclinically for liver-protective effects.
- Metabolic and endocrine system: Validated antidiabetic properties are supported by both traditional use and modern scientific evidence.
- Immune and inflammatory system: Pharmacological activities reported include anti-inflammatory, antiallergic, antioxidant, and antitumor activities.
- Integumentary system (skin and wound healing): Modern pharmacological studies have shown wound healing, antileishmanial, and antimicrobial properties.
- Respiratory system: Leaves and roots have been used traditionally in bronchitis and cough by herbalists in countries such as Oman and the UAE.
- Digestive/gastrointestinal system: According to Ayurveda, the plant is digestible, anthelmintic, alexiteric, antipyretic, and cures diseases of liver, spleen, heart, blood, tumours, ulcers, leprosy, and asthma.
- Cardiovascular system: Used in Ayurveda for heart conditions, with preclinical cardioprotective data in diabetic animal models.
- Neurological system: Acetylcholinesterase inhibitory action reported from this plant aids its potential utilization for the development of drugs for Alzheimer's and dementia neurological disorders.
7. Dosage Forms and Dosages Reported in Sources
No standardized human clinical doses have been established through controlled clinical trials. The following dosage information reflects what has been reported in Ayurvedic literature and in preclinical research:
- Crude powder (churna), Ayurvedic literature: Powder: 1–3 grams twice daily with warm water or honey. Other Ayurvedic sources report the typical adult dose of 3–6 g of root powder per day, divided into two doses.
- Decoction (kashaya), Ayurvedic literature: Decoction: 30–50 ml twice daily or as directed by an Ayurvedic practitioner. Decoction of the whole plant with Phyllanthus niruri and cumin seeds for jaundice and hepatitis is advised in 20–30 ml doses, 3–4 times a day.
- Root decoction, Ayurvedic literature: A root decoction for indigestion, flatulence, and loss of taste/hunger uses 3–5 grams of root material.
- Ethanolic seed extract in animal antidiabetic research: Oral administration at a dose of 300 mg/kg body weight in streptozotocin-induced diabetic rats showed significant antihyperglycemic and antilipidperoxidative effects.
- Aqueous extract in animal cardiology research: Treatment of diabetic rats at 300 and 500 mg/kg orally decreased cardiac LVH and reduced LDH and CK at 500 mg/kg.
- Topical ointment in wound healing research: An ointment at 5% w/w of the ethyl acetate fraction of T. purpurea was applied topically twice daily in animal wound models.
- Acute toxicity threshold (preclinical): An acute toxicity study found the extract was safe up to a dose of 2000 mg/kg in rodent models.
No clinically validated human dosing guidelines have been established through randomized controlled trials as of the most recent reviews. Further clinical research is needed to standardize formulations and establish dosing protocols.
8. Safety Considerations and Interactions
8.1 General Toxicological Profile
Toxicological studies confirm safety at doses ≤2000 mg/kg in rodent models, though caution is advised for prolonged use due to potential rotenoid-mediated mitochondrial effects.
From different toxicological studies, concentrations up to 2,000 mg/kg were considered safe.
Further clinical trials are needed to standardize dosages and evaluate long-term efficacy and safety in humans.
8.2 Rotenoid-Specific Safety Concerns
Rotenonoids, which are present in Tephrosia purpurea, are classified by the World Health Organization as moderately hazardous. They are mildly toxic to humans and other mammals, but extremely toxic to many insects and aquatic life, including fish. This higher toxicity in fish and insects is because the lipophilic rotenonoid is easily taken up through the gills or trachea, but not as easily through the skin or the gastrointestinal tract.
The lowest lethal dose for a child is recorded as 143 mg/kg, but human deaths from rotenone poisoning are rare because its irritating action causes vomiting. Deliberate ingestion of rotenone, however, can be fatal.
Particularly due to its rotenoid content (i.e., rotenone, deguelin, rotenolone, and tephrosin), several Tephrosia species are known to be toxic to insects, fish, and mammals.
The rotenoid class is also associated, based on separate epidemiological and experimental research, with concerns about mitochondrial electron transport chain inhibition at the level of Complex I; this is the same mechanism underlying some experimental neurotoxicity models.
8.3 Antifertility/Antispermatogenic Effect
Animal data showed degenerated germinal epithelium of seminiferous tubules and reduced sperm number in a dose-dependent manner following T. purpurea treatment. Treatment at 100 and 200 mg/kg/body weight/day affected almost all tubules; however, spermatogenesis recovered near-normal levels in recovery-group rats.
This is an experimentally documented effect in rodents that has not been studied in humans, but represents a relevant caution for populations where reproductive health is a consideration.
8.4 Potential Drug Interactions
Modern pharmacological studies have shown that the plant has hepatoprotective, antifertility, antispermatogenic, anti-diarrheal, and diuretic properties.
Its hepatic activity suggests that constituents metabolized by or affecting cytochrome P450 enzymes could theoretically interact with co-administered pharmaceuticals metabolized by the same pathways, though specific human pharmacokinetic interaction data are not available in the peer-reviewed literature. The rotenoid compounds' inhibition of mitochondrial Complex I has relevance for co-administration with other mitochondrial-active agents.
8.5 Evidence Strength Summary
Most of the reported biological activity requires further testing against a wide range of diseases, though they can be recommended as possible promising compounds.
Tephrosia purpurea emerges as a versatile medicinal plant with validated hepatoprotective, antidiabetic, neuroprotective, and wound-healing properties, supported by both traditional use and modern scientific evidence. Its rich phytochemical profile, particularly flavonoids and rotenoids, underpins its broad therapeutic potential. While preclinical studies demonstrate efficacy and safety at therapeutic doses, further clinical research is needed to standardize formulations and establish dosing protocols.
In summary, virtually all pharmacological evidence beyond traditional use reports is preclinical (animal or in vitro). No large, well-designed, randomized controlled trials in humans have been published for any indication. The plant's incorporation into commercial hepatoprotective formulations and its use in Ayurvedic practice rest primarily on traditional knowledge and supportive, but not conclusive, preclinical research.
References
Go back